15,508 Shares in Arcellx, Inc. $ACLX Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd bought a new stake in shares of Arcellx, Inc. (NASDAQ:ACLX) during the 3rd quarter, HoldingsChannel reports. The firm bought 15,508 shares of the company’s stock, valued at approximately $1,273,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Schroder Investment Management Group purchased a new position in shares of Arcellx during the second quarter valued at approximately $3,951,000. American Century Companies Inc. boosted its holdings in Arcellx by 694.3% in the second quarter. American Century Companies Inc. now owns 431,466 shares of the company’s stock worth $28,412,000 after purchasing an additional 377,145 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its position in Arcellx by 7.1% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 3,428 shares of the company’s stock worth $226,000 after purchasing an additional 228 shares during the period. Decheng Capital LLC raised its stake in Arcellx by 995.2% during the 2nd quarter. Decheng Capital LLC now owns 547,609 shares of the company’s stock valued at $36,060,000 after buying an additional 497,609 shares during the last quarter. Finally, Jefferies Financial Group Inc. bought a new position in shares of Arcellx during the 2nd quarter valued at $856,000. Institutional investors own 96.03% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the company. Guggenheim reaffirmed a “buy” rating on shares of Arcellx in a report on Monday, November 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcellx in a research report on Wednesday, January 21st. Citigroup reaffirmed a “buy” rating on shares of Arcellx in a research report on Monday, November 24th. Stifel Nicolaus set a $129.00 price objective on shares of Arcellx and gave the stock a “buy” rating in a report on Thursday, October 16th. Finally, Wolfe Research assumed coverage on shares of Arcellx in a research report on Tuesday, November 18th. They set a “peer perform” rating for the company. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $112.22.

Arcellx Price Performance

ACLX opened at $68.31 on Friday. The company has a 50 day simple moving average of $68.06 and a two-hundred day simple moving average of $74.97. The firm has a market cap of $3.95 billion, a P/E ratio of -17.38 and a beta of 0.36. Arcellx, Inc. has a 1-year low of $47.86 and a 1-year high of $94.07.

Arcellx (NASDAQ:ACLX) last released its earnings results on Wednesday, November 5th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.03). Arcellx had a negative return on equity of 51.13% and a negative net margin of 607.01%.The business had revenue of $4.95 million for the quarter, compared to analysts’ expectations of $11.24 million. Equities analysts anticipate that Arcellx, Inc. will post -1.58 earnings per share for the current year.

Insider Buying and Selling at Arcellx

In other news, insider Christopher Heery sold 7,437 shares of Arcellx stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $65.51, for a total value of $487,197.87. Following the sale, the insider directly owned 29,631 shares of the company’s stock, valued at approximately $1,941,126.81. The trade was a 20.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 19,790 shares of company stock worth $1,314,077 in the last ninety days. Company insiders own 8.35% of the company’s stock.

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.